Detection of Microdeletions in the Azoospermia Factor (AZF) Regions in Infertile Male Patients

Overview

In this prospective study, we used Multiplex ligation-dependent probe amplification and next-generation sequencing technology to detect AZF microdeletion types accurately in selected genetic locus, and made correlation analysis with clinical treatment results.

Full Title of Study: “Detection of Microdeletions in the Azoospermia Factor (AZF) Regions on the Human Y Chromosome in Infertile Male Patients”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 1, 2021

Detailed Description

Infertility has plagued more than 10% of the world's couples of childbearing age, of which male factors account for half. There are many causes of male infertility, including infection, genital malformations, immune dysfunction, varicocele, erectile dysfunction, drug side effect and chromosomal abnormality. Microdeletion of Azoospermia factor (AZF) in the long arm of the Y chromosome is one of the main genetic factors leading to dyszoospermia. The incidence of AZF microdeletions is 2%~19.4% among male infertile patients in Asia, which is related to the inclusion criteria, STS site selection, population and genetic background. At present, there are large numbers of studies on AZF microdeletions in male infertility, and provide rich information on male infertility. However, as the main means of detection is multiplex PCR-capillary electrophoresis method, which usually detects sequence-tagged sites(STS) such as AZFa-sY84,sY86,AZFb-sY127,sY134,AZFc- sY1191, sY1291, sY1189,sY254 and sY255, information on other loci is still lacking. In addition, the shortcomings of this method include false positive and false negative results caused by fuzzy electrophoresis strip or pollution and the presence of high repetition and a large number of palindrome in complex AZF region. Because some microdeletions can't be detected it is difficult to make an accurate judgement on the fertility of the patients. This study will use Multiplex ligation-dependent probe amplification and NGS method to improve the detection rate of AZF microdeletion, and analyze the microdeletion data and the patient's fertility results, so as to improve genetic counseling. A total of 5000 male infertility patients will be enrolled. At least 1000 parents and 1000 normal fertile men will be asked to donate their peripheral blood for DNA. In addition, in patients with azoospermia or severe oligozoospermia, the overall deletion rate of AZF is about 8.77% (1.75%-24.70%), so there are other unknown genetic factors leading to azoospermia or severe oligozoospermia. This study will also try to make a preliminary study of these factors.

Clinical Trial Outcome Measures

Primary Measures

  • frequency of mirodeletion
    • Time Frame: through study completion, an average of 1 year
    • The propotion of azoospermia patients with AZF mirodeletion

Participating in This Clinical Trial

Inclusion Criteria

-Male patients diagnosed with azoospermia and severe oligozoospermia. Exclusion Criteria:

1. Klinefelter Syndrome ; 2. Structural chromosome aberrations; 3. Obstructive anspermia; 4. Male infertility caused by endocrine factors; 5. Do not meet requirements for acquisition, processing and preservation of samples; 6. After sampling, it doesn't conform to the standard of quality control, or other experimental conditions that don't meet the test requirement; 7. Unable to obtain patient history;

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Reproductive & Genetic Hospital of CITIC-Xiangya
  • Collaborator
    • Anhui Provincial Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Yueqiu Tan, Study Chair, Reproductive & Genetic Hospital of CITIC-Xiangya

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.